Оглавление
Группа авторов. Recent Advances in the Pathogenesis and Treatment of Kidney Diseases
Contributions to Nephrology
Recent Advances in the Pathogenesis and Treatment of Kidney Diseases
Contents
Preface
The Role of Caveolae on Albumin Passage through Glomerular Endothelial and Epithelial Cells: The New Etiology of Urinary Albumin Excretion
Abstract
The Roles of Caveolae
The Roles of Caveolae in the Kidney
Albumin Transportation through Caveolae. Glomerular Endothelial Cells
Glomerular Epithelial Cells
New Intracellular Trafficking Pathway of Albumin through Glomerular Endothelial and Epithelial Cells
Conclusions
Acknowledgements
References
Rituximab as a Therapeutic Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in Adults
Abstract
Mechanism of Rituximab Action
Pharmacokinetics of Rituximab Infusion
Single-Dose Rituximab Therapy for Steroid-Dependent MCNS
Side Effects of Rituximab Treatment
Perspectives
Conclusion
References
Large Renal Corpuscle: Clinical Significance of Evaluation of the Largest Renal Corpuscle in Kidney Biopsy Specimens
Abstract
Significance of Large Renal Corpuscles
Experimental Models. Remnant Kidney Model
Type II Diabetic Rats
Humans
Renal Allografts
Obesity-Related Glomerulopathy
Physiological or Morbid Enlargement?
Problems in the Measurement of Renal Corpuscle Size (Glomerular Size)
Morphometric Methods
Mean Value or Maximum Value?
Acknowledgments
Key Messages
References
New Insights into Cystic Kidney Diseases
Abstract
Cilia
Ciliopathy
Classification of Hereditary Cystic Kidney Diseases (Fig. 1, 2)
Autosomal Recessive Polycystic Kidney Disease
Nephronophthisis
Infantile NPHP
Juvenile NPHP
Adolescent NPHP
NPHP-Related Disorders
Senior-Loken Syndrome
Joubert Syndrome (JBTS; Cerebro-Oculo-Renal Syndrome)
Meckel-Gruber Syndrome
Bardet-Biedl Syndrome
Oral-Facial-Digital Syndrome
Autosomal Dominant Tubulointerstitial Kidney Disease
Autosomal Dominant Tubulointerstitial Kidney Disease-MUC1: Medullary Cystic Kidney Disease Type 1
ADTKD-UMOD: MCKD2
ADTKD-REN: Familial Juvenile Hyperurecemic Nephropathy Type 2
ADTKD-HNFIB: HNF1β-Related Disease
Autosomal Dominant Polycystic Kidney Disease
Conclusion
References
Recent Advances in Treatment Strategies for Lupus Nephritis
Abstract
Immunological Therapy
Induction Therapy
Maintenance Therapy
Newer Biological Agents
Non-Immunological Therapy. Hydroxychloroquine
Anti-Hypertensive Agents
Hyperlipidemia Treatment Strategies
Conclusion
References
Association between Increases in Normalized Protein Catabolic Rate and Increases in Creatinine Generation Rate in Dialysis Patients
Abstract
Methods. Study Design
Statistical Analysis
Ethical Issues
Results. Patient Background and Treatment Characteristics
Laboratory Findings
nPCR Changes and %CGR Changes
Multivariate Analyses
Sensitivity Analyses
Discussion
References
Renal Anemia and Iron Metabolism
Abstract
Iron Management Standards and Guidelines
Hematopoiesis and Iron Metabolism
Iron Absorption and Mucosal Block
Iron Metabolism and Patients on Hemodialysis
ESA and Iron Metabolism
Studies Regarding Optimal Levels of Iron and Hb Levels
Conclusion
Acknowledgement
References
Cell Sheet Engineering and Kidney Diseases
Abstract
Application of Cell Sheet Therapy
Renal Impairment and Cell Therapy
Application of Cell Sheet Technology to the Kidney
Conclusion
References
Clinical Impact of Left Ventricular Diastolic Dysfunction in Chronic Kidney Disease
Abstract
Pathogenesis
LVH with Myocardial Fibrosis in CKD
Clinical Measurement of DD
Treatment
Conclusion
References
Treatment of Posttransplantation Anemia
Abstract
Renal Anemia
Epidemiology of Posttransplantation Anemia
Causes of PTA
Early PTA and Maintenance-Phase PTA
Early PTA
Maintenance-Phase PTA
Treatment of PTA. Erythropoiesis-Stimulating Agent
Iron Preparations
Blood Transfusion
Conclusion
References
Role of Frailty on Outcomes of Dialysis Patients
Abstract
Definition of Frailty
Prevalence of Frailty in the Dialysis Population
Screening and Management of Frailty
Interventions for Frail Older Adults
Perspectives
Conclusion
References
Socioeconomics of Administering Rituximab for Nephrotic Syndrome
Abstract
Concept of Cost-Effectiveness and Objectives of the Study
Methods. Study Population
Outcomes: Clinical and Economic Indicators
Trial Protocol
Results. Characteristics of the Study Population
Changes in the Effectiveness Parameters
Change of the Cost Parameter
Result of the CEA
Discussion
Conclusion
References
Use of Beta-Blockers on Maintenance Dialysis Patients and Ischemic Cerebral and Cardiovascular Deaths: An Examination Using Propensity Score
Abstract
Subjects/Methods
Results. Patient Backgrounds and Prognoses
Survival Analyses and Prognostic Factors
Discussion
Limitations
Conclusion
References
Direct Effects of Immunomodulatory Agents on Podocytes in Immune-Mediated Glomerular Diseases
Abstract
Consequence of Podocyte Injury
Direct Effects of Immunomodulatory Agents on Podocytes GCs (Fig. 2a)
Calcineurin Inhibitors (Fig. 2b)
Purine Synthesis Inhibitors (Fig. 2c)
Levamisole (Fig. 2a)
Mammalian Target of Rapamycin Inhibitors (Fig. 2d)
Anti-CD20 Antibodies (Fig. 2e)
Cytotoxic T Lymphocyte Associated Antigen-4/Immunoglobulin Fusion Proteins (Fig. 2f)
Conclusion
References
Author Index
Subject Index
